{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T15:52:36Z","timestamp":1742917956580,"version":"3.40.3"},"publisher-location":"Cham","reference-count":55,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030504939"},{"type":"electronic","value":"9783030504946"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/164_2019_305","type":"book-chapter","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T13:20:02Z","timestamp":1591708802000},"page":"87-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacotherapy in Rare Skeletal Diseases"],"prefix":"10.1007","author":[{"given":"Heike","family":"Hoyer-Kuhn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckhard","family":"Sch\u00f6nau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"issue":"2","key":"305_CR1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2006.03.013","volume":"149","author":"F Antoniazzi","year":"2006","unstructured":"Antoniazzi F, Zamboni G et al (2006) Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 149(2):174\u2013179","journal-title":"J Pediatr"},{"issue":"4","key":"305_CR2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ajhg.2012.02.026","volume":"90","author":"PV Asharani","year":"2012","unstructured":"Asharani PV, Keupp K et al (2012) Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish. Am J Hum Genet 90(4):661\u2013674","journal-title":"Am J Hum Genet"},{"issue":"1","key":"305_CR3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1651-2227.1998.tb01388.x","volume":"87","author":"E Astrom","year":"1998","unstructured":"Astrom E, Soderhall S (1998) Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 87(1):64\u201368","journal-title":"Acta Paediatr"},{"issue":"3","key":"305_CR4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ajhg.2011.01.015","volume":"88","author":"J Becker","year":"2011","unstructured":"Becker J, Semler O et al (2011) Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 88(3):362\u2013371","journal-title":"Am J Hum Genet"},{"issue":"2","key":"305_CR5","first-page":"170","volume":"12","author":"N Bishop","year":"2015","unstructured":"Bishop N (2015) Clinical management of hypophosphatasia. Clin Cases Miner Bone Metab 12(2):170\u2013173","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"9902","key":"305_CR6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","volume":"382","author":"N Bishop","year":"2013","unstructured":"Bishop N, Adami S et al (2013) Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 382(9902):1424\u20131432","journal-title":"Lancet"},{"issue":"7","key":"305_CR7","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","volume":"27","author":"AM Boyce","year":"2012","unstructured":"Boyce AM, Chong WH et al (2012) Denosumab treatment for fibrous dysplasia. J Bone Miner Res 27(7):1462\u20131470","journal-title":"J Bone Miner Res"},{"key":"305_CR8","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.6061\/clinics\/2018\/e324","volume":"73","author":"JRM Ceroni","year":"2018","unstructured":"Ceroni JRM, Soares DCQ et al (2018) Natural history of 39 patients with Achondroplasia. Clinics (Sao Paulo) 73:e324","journal-title":"Clinics (Sao Paulo)"},{"issue":"6","key":"305_CR9","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1210\/jc.2005-2548","volume":"91","author":"B Chan","year":"2006","unstructured":"Chan B, Zacharin M (2006) Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 91(6):2017\u20132020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"305_CR10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"issue":"6","key":"305_CR11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ajmg.a.61120","volume":"179","author":"M Del Pino","year":"2019","unstructured":"Del Pino M, Fano V et al (2019) Height growth velocity during infancy and childhood in achondroplasia. Am J Med Genet A 179(6):1001\u20131009","journal-title":"Am J Med Genet A"},{"issue":"10028","key":"305_CR12","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","volume":"387","author":"A Forlino","year":"2016","unstructured":"Forlino A, Marini JC (2016) Osteogenesis imperfecta. Lancet 387(10028):1657\u20131671","journal-title":"Lancet"},{"issue":"1","key":"305_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ghir.2006.10.004","volume":"17","author":"O Fricke","year":"2007","unstructured":"Fricke O, Schoenau E (2007) The \u2018Functional Muscle-Bone Unit\u2019: probing the relevance of mechanical signals for bone development in children and adolescents. Growth Hormon IGF Res 17(1):1\u20139","journal-title":"Growth Hormon IGF Res"},{"issue":"5","key":"305_CR14","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","volume":"20","author":"D Gatti","year":"2005","unstructured":"Gatti D, Antoniazzi F et al (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20(5):758\u2013763","journal-title":"J Bone Miner Res"},{"issue":"Suppl 2","key":"305_CR15","doi-asserted-by":"crossref","first-page":"P110","DOI":"10.1359\/jbmr.06s221","volume":"21","author":"FH Glorieux","year":"2006","unstructured":"Glorieux FH, Rauch F (2006) Medical therapy of children with fibrous dysplasia. J Bone Miner Res 21(Suppl 2):P110\u2013P113","journal-title":"J Bone Miner Res"},{"issue":"6","key":"305_CR16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/8756-3282(96)87996-8","volume":"17","author":"FH Glorieux","year":"1995","unstructured":"Glorieux FH, Travers R et al (1995) Pamidronate treatment in children with fibrous dysplasia and osteogenesis imperfecta. Bone 17(6):611\u2013611","journal-title":"Bone"},{"issue":"14","key":"305_CR17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ et al (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339(14):947\u2013952","journal-title":"N Engl J Med"},{"issue":"7","key":"305_CR18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","volume":"32","author":"FH Glorieux","year":"2017","unstructured":"Glorieux FH, Devogelaer JP et al (2017) BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J Bone Miner Res 32(7):1496\u20131504","journal-title":"J Bone Miner Res"},{"issue":"8","key":"305_CR19","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1210\/jc.2013-1143","volume":"98","author":"C Grasemann","year":"2013","unstructured":"Grasemann C, Schundeln MM et al (2013) Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget\u2019s disease. J Clin Endocrinol Metab 98(8):3121\u20133126","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"305_CR20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ejhg.2014.10","volume":"22","author":"C Hofmann","year":"2014","unstructured":"Hofmann C, Girschick H et al (2014) Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia. Eur J Hum Genet 22(10):1160\u20131164","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"305_CR21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","volume":"9","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn H, Netzer C et al (2014a) Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis 9(1):145","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"305_CR22","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1210\/jc.2014-3072","volume":"99","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn H, Semler O et al (2014b) Effect of denosumab on the growing skeleton in osteogenesis imperfecta. J Clin Endocrinol Metab 99(11):3954\u20133955","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"305_CR23","first-page":"445","volume":"14","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn H, Semler O et al (2014c) A specialized rehabilitation approach improves mobility in children with osteogenesis imperfecta. J Musculoskelet Neuronal Interact 14(4):445\u2013453","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"4","key":"305_CR24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00112-016-0189-5","volume":"165","author":"H Hoyer-Kuhn","year":"2016","unstructured":"Hoyer-Kuhn H, Bartz-Seel J et al (2016a) Diagnostik und therapie der osteogenesis imperfecta. Monatsschr Kinderheilkd 165(4):333\u2013346","journal-title":"Monatsschr Kinderheilkd"},{"issue":"1","key":"305_CR25","first-page":"24","volume":"16","author":"H Hoyer-Kuhn","year":"2016","unstructured":"Hoyer-Kuhn H, Franklin J et al (2016b) Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial. J Musculoskelet Neuronal Interact 16(1):24\u201332","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"8","key":"305_CR26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00112-017-0321-1","volume":"165","author":"H Hoyer-Kuhn","year":"2017","unstructured":"Hoyer-Kuhn H, Rehberg M et al (2017) Angeborene skeletterkrankungen. Monatsschr Kinderheilkd 165(8):663\u2013671","journal-title":"Monatsschr Kinderheilkd"},{"issue":"1","key":"305_CR27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","volume":"14","author":"MK Javaid","year":"2019","unstructured":"Javaid MK, Boyce A et al (2019) Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium. Orphanet J Rare Dis 14(1):139","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"305_CR28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ajhg.2013.02.010","volume":"92","author":"K Keupp","year":"2013","unstructured":"Keupp K, Beleggia F et al (2013) Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet 92(4):565\u2013574","journal-title":"Am J Hum Genet"},{"issue":"2","key":"305_CR29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1651-2227.2000.tb01214.x","volume":"89","author":"R Lala","year":"2000","unstructured":"Lala R, Matarazzo P et al (2000) Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 89(2):188\u2013193","journal-title":"Acta Paediatr"},{"issue":"4","key":"305_CR30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jpeds.2005.10.041","volume":"148","author":"C Land","year":"2006","unstructured":"Land C, Rauch F et al (2006) Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr 148(4):456\u2013460","journal-title":"J Pediatr"},{"issue":"3","key":"305_CR31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","volume":"40","author":"C Land","year":"2007","unstructured":"Land C, Rauch F et al (2007) Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone 40(3):638\u2013644","journal-title":"Bone"},{"key":"305_CR32","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.52","volume":"3","author":"JC Marini","year":"2017","unstructured":"Marini JC, Forlino A et al (2017) Osteogenesis imperfecta. Nat Rev Dis Primers 3:17052","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"305_CR33","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ajhg.2015.04.021","volume":"96","author":"R Mendoza-Londono","year":"2015","unstructured":"Mendoza-Londono R, Fahiminiya S et al (2015) Recessive osteogenesis imperfecta caused by missense mutations in SPARC. Am J Hum Genet 96(6):979\u2013985","journal-title":"Am J Hum Genet"},{"issue":"1","key":"305_CR34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000446958","volume":"86","author":"M Miccoli","year":"2016","unstructured":"Miccoli M, Bertelloni S et al (2016) Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis. Horm Res Paediatr 86(1):27\u201334","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"305_CR35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2015-2175","volume":"101","author":"CF Munns","year":"2016","unstructured":"Munns CF, Shaw N et al (2016) Global consensus recommendations on prevention and management of nutritional rickets. J Clin Endocrinol Metab 101(2):394\u2013415","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"305_CR36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00774-009-0149-4","volume":"28","author":"I Panigrahi","year":"2010","unstructured":"Panigrahi I, Das RR et al (2010) Response to zolendronic acid in children with type III osteogenesis imperfecta. J Bone Miner Metab 28(4):451\u2013455","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"305_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0972-6","volume":"14","author":"RM Pauli","year":"2019","unstructured":"Pauli RM (2019) Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis 14(1):1","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"305_CR38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00590-014-1496-y","volume":"25","author":"V Pavone","year":"2015","unstructured":"Pavone V, Testa G et al (2015) Hypophosphatemic rickets: etiology, clinical features and treatment. Eur J Orthop Surg Traumatol 25(2):221\u2013226","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"305_CR39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bone.2016.09.013","volume":"93","author":"JE Perosky","year":"2016","unstructured":"Perosky JE, Khoury BM et al (2016) Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl\/+ osteogenesis imperfecta model. Bone 93:79\u201385","journal-title":"Bone"},{"issue":"10","key":"305_CR40","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1210\/jc.2003-030050","volume":"88","author":"H Plotkin","year":"2003","unstructured":"Plotkin H, Rauch F et al (2003) Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 88(10):4569\u20134575","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"305_CR41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ajhg.2014.12.027","volume":"96","author":"F Rauch","year":"2015","unstructured":"Rauch F, Fahiminiya S et al (2015) Cole-Carpenter syndrome is caused by a heterozygous missense mutation in P4HB. Am J Hum Genet 96(3):425\u2013431","journal-title":"Am J Hum Genet"},{"issue":"1","key":"305_CR42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJMoa1813446","volume":"381","author":"R Savarirayan","year":"2019","unstructured":"Savarirayan R, Irving M et al (2019) C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med 381(1):25\u201335","journal-title":"N Engl J Med"},{"issue":"5","key":"305_CR43","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00223-001-0048-8","volume":"70","author":"E Schoenau","year":"2002","unstructured":"Schoenau E, Frost HM (2002) The \u201cmuscle-bone unit\u201d in children and adolescents. Calcif Tissue Int 70(5):405\u2013407","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"305_CR44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000331128","volume":"76","author":"O Semler","year":"2011","unstructured":"Semler O, Beccard R et al (2011) Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta. Horm Res Paediatr 76(5):321\u2013327","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"305_CR45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ajhg.2012.06.011","volume":"91","author":"O Semler","year":"2012","unstructured":"Semler O, Garbes L et al (2012a) A mutation in the 5\u2032-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet 91(2):349\u2013357","journal-title":"Am J Hum Genet"},{"issue":"3","key":"305_CR46","first-page":"183","volume":"12","author":"O Semler","year":"2012","unstructured":"Semler O, Netzer C et al (2012b) First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 12(3):183\u2013188","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"4","key":"305_CR47","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","volume":"113","author":"T Shimada","year":"2004","unstructured":"Shimada T, Kakitani M et al (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113(4):561\u2013568","journal-title":"J Clin Invest"},{"issue":"5","key":"305_CR48","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M et al (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38(5):525\u2013527","journal-title":"Nat Genet"},{"issue":"18","key":"305_CR49","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1056\/NEJMc1206193","volume":"367","author":"R Shroff","year":"2012","unstructured":"Shroff R, Beringer O et al (2012) Denosumab for post-transplantation hypercalcemia in osteopetrosis. N Engl J Med 367(18):1766\u20131767","journal-title":"N Engl J Med"},{"issue":"26","key":"305_CR50","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","volume":"325","author":"CF Verge","year":"1991","unstructured":"Verge CF, Lam A et al (1991) Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 325(26):1843\u20131848","journal-title":"N Engl J Med"},{"issue":"3","key":"305_CR51","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1210\/jc.2013-3081","volume":"99","author":"HD Wang","year":"2014","unstructured":"Wang HD, Boyce AM et al (2014) Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab 99(3):891\u2013897","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"305_CR52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.14","volume":"12","author":"MP Whyte","year":"2016","unstructured":"Whyte MP (2016) Hypophosphatasia \u2013 aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 12(4):233\u2013246","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"305_CR53","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1106173","volume":"366","author":"MP Whyte","year":"2012","unstructured":"Whyte MP, Greenberg CR et al (2012) Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 366(10):904\u2013913","journal-title":"N Engl J Med"},{"issue":"3","key":"305_CR54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO et al (2019) Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol 7(3):189\u2013199","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"305_CR55","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jbmr.2154","volume":"29","author":"BO Williams","year":"2014","unstructured":"Williams BO (2014) Insights into the mechanisms of sclerostin action in regulating bone mass accrual. J Bone Miner Res 29(1):24\u201328","journal-title":"J Bone Miner Res"}],"container-title":["Handbook of Experimental Pharmacology","Pediatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2019_305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T10:48:41Z","timestamp":1666867721000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2019_305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030504939","9783030504946"],"references-count":55,"URL":"https:\/\/doi.org\/10.1007\/164_2019_305","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"type":"print","value":"0171-2004"},{"type":"electronic","value":"1865-0325"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"10 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}